Targeted therapies, particularly EGFR tyrosine kinase inhibitors (TKIs), have become a cornerstone of care in EGFR-mutated NSCLC, leading to substantial gains in survival and quality of life compared with conventional chemotherapy (1–3). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.